A forum peptide dose is not a minimum

There is no established minimum human dose of BPC-157 or TB-500 for tissue repair. A community post cited a number repeated in other posts and asked whether a slightly smaller amount, used more often, would still be adequate. That question assumes a human dose-response study exists. It does not. The familiar forum numbers come mainly from animal experiments, body-size conversions, and repetition.

A minimum dose is the lowest exposure shown to produce a defined benefit in a defined population. For these products, neither half of that sentence has been established in a controlled human repair trial. There is no validated threshold and no evidence-based frequency to adjust around a budget.

What the BPC-157 experiments measured

BPC-157 has a sizable preclinical record. In a 2006 rat model, researchers detached the Achilles tendon from the heel bone and administered BPC-157 while measuring tendon-to-bone healing^[1]. A 2010 rat study examined healing after medial collateral ligament transection and used several routes, including injection, oral delivery, and topical application^[2]. These papers can support a statement about injured rats under those laboratory conditions. They do not establish a minimum for a person with a shoulder, tendon, back, or postsurgical problem.

A separate preclinical safety and pharmacokinetic programme tested much larger weight-based exposures in rats and dogs and proposed a possible first human starting figure^[3]. A proposed starting point is not a therapeutic dose. It is the sort of estimate researchers might carry into early human testing, where safety, concentration, route, and dose response would still need to be measured.

TB-500 adds a naming problem

TB-500 is sold as a fragment associated with thymosin beta-4, but online discussions often move between the fragment, the full protein, and different commercial mixtures as if they were interchangeable. They are not. A study of full-length thymosin beta-4 does not automatically establish the pharmacology of a fragment sold under an informal product name.

A 2026 sports-medicine review examined the injectable peptide market and the underlying literature. For products such as BPC-157 and thymosin-related peptides, it found a sharp mismatch between public claims and clinical evidence. The authors described major gaps in indications, dose, frequency, and treatment duration^[4]. That is the opposite of an established minimum.

Why animal-to-human maths is not a protocol

Body-surface-area conversion is a legitimate tool for estimating a cautious starting exposure in drug development. It adjusts a dose reported in milligrams or micrograms per kilogram across species. What it cannot do is predict whether the converted amount repairs a human tendon, how often it should be given, or whether repeated use is safe.

The route matters too. The BPC-157 literature includes intraperitoneal, intramuscular, intravenous, oral, topical, and local administration^[2][3]. Subcutaneous schedules repeated in forums do not inherit evidence from every other route. Absorption and exposure can differ, and grey-market concentration adds another unknown before any conversion begins.

Frequency cannot rescue an unknown dose

Using an unvalidated amount twice instead of once does not produce a validated total. Frequency depends on pharmacokinetics, which includes how quickly a compound enters circulation, reaches tissue, and is cleared. It also depends on the endpoint. Pain relief, structural healing on imaging, and return to function are not the same outcome.

The published preclinical pharmacokinetic work reported a short measured half-life for BPC-157 in animals^[3]. That finding does not prove that frequent human injections are effective or safe. A short blood half-life can coexist with longer downstream biological effects, or with no meaningful human effect at all. Only a human dose-finding programme can sort those possibilities.

The budget question changes the decision

When cost is driving someone to stretch a vial, the answer should not be a cheaper internet protocol. It should be a clearer look at what is being purchased. Neither compound has an approved human repair indication, and a research-chemical vial has no licensed assurance of identity, concentration, or sterility. Spending less per injection does not improve that evidence base.

For injury questions, start with a diagnosis and treatments whose benefit can be measured. Our BPC-157 evidence page, TB-500 evidence page, and injury-recovery evidence overview show where animal findings stop. A clinician or physiotherapist can also identify cases where continuing to load an injury is the real obstacle.

What we do not know

We do not know a minimum effective human amount, the best route, a safe repeated-use frequency, or whether BPC-157 and TB-500 together outperform either alone. We also do not know whether a given vial contains the amount on its label. Those gaps are why this article does not publish a schedule. It is educational and journalistic, not medical advice. Discuss an injury and any product you are considering with a qualified healthcare professional.